Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2016 - 2022)

Intellia Therapeutics has reported Other Non-Current Liabilities over the past 5 years, most recently at $24.0 million for Q4 2022.

  • Quarterly Other Non-Current Liabilities changed N/A to $24.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2022, changed N/A year-over-year, with the annual reading at $24.0 million for FY2022, N/A changed from the prior year.
  • Other Non-Current Liabilities was $24.0 million for Q4 2022 at Intellia Therapeutics, up from $18.6 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $24.0 million in Q4 2022 and troughed at $13000.0 in Q4 2018.